产品
编 号：F756854
分子式：C22H23ClN4OS
分子量：426.96
分子式：C22H23ClN4OS
分子量：426.96
产品类型
规格
价格
是否有货
结构图
CAS No: 2919691-32-8
产品详情
生物活性：
HDAC2-IN-1 (Compound 17) is a brain penetrant, orally active, competitive HDAC2 inhibitor with an IC50 of 0.5 μM. HDAC2-IN-1 also inhibits HDAC1 and HDAC8 with IC50s of 1.61 μM and 0.98 μM, respectively.
体内研究：
HDAC2-IN-1 (Compound 17) (30 or 100 mg/kg; p.o.; once) shows good plasma and brain exposure, and shows promising brain penetration.Animal Model:Male C57BL/6 mice
Dosage:30 or 100 mg/kg
Administration:Oral administration (Pharmacokinetic Analysis)
Result:Showed good plasma and brain exposure, also showed promising brain penetration, Kp,uu = 0.36. Significantly increased histone H4K12 acetylation in mouse brain 4 h after oral dosing at 100 mg/kg.
体外研究：
HDAC2-IN-1 (Compound 17) (3 and 10 μM; 48 h) increases histone H4K12 and H3K9 acetylation levels in SKNSH cells in a dose-dependent manner.
HDAC2-IN-1 (Compound 17) is a brain penetrant, orally active, competitive HDAC2 inhibitor with an IC50 of 0.5 μM. HDAC2-IN-1 also inhibits HDAC1 and HDAC8 with IC50s of 1.61 μM and 0.98 μM, respectively.
体内研究：
HDAC2-IN-1 (Compound 17) (30 or 100 mg/kg; p.o.; once) shows good plasma and brain exposure, and shows promising brain penetration.Animal Model:Male C57BL/6 mice
Dosage:30 or 100 mg/kg
Administration:Oral administration (Pharmacokinetic Analysis)
Result:Showed good plasma and brain exposure, also showed promising brain penetration, Kp,uu = 0.36. Significantly increased histone H4K12 acetylation in mouse brain 4 h after oral dosing at 100 mg/kg.
体外研究：
HDAC2-IN-1 (Compound 17) (3 and 10 μM; 48 h) increases histone H4K12 and H3K9 acetylation levels in SKNSH cells in a dose-dependent manner.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备